Toca 5 Clinical Trial

Tocagen’s initial proposed indication, recurrent high-grade glioma, or HGG, is the most common and aggressive primary brain cancer. The two most common forms of HGG are glioblastoma and anaplastic astrocytoma. HGG recurs in most patients, even after maximal treatment. Participation in a clinical trial is one possible option for people who have regrowth of these types of brain cancers. It is recommended that patients talk with their doctor to discuss potential participation in a clinical trial.

Tocagen is conducting a Phase 3 clinical trial, called Toca 5, for patients with recurrent HGG. The study is being conducted at 67 sites globally. Patients undergoing resection for first or second recurrence of glioblastoma (GBM) or anaplastic astrocytoma (AA) are eligible.

You may view a list of sites across the United States, Canada, Israel and South Korea where the trial is ongoing. Learn more about the study by visiting ClinicalTrials.gov, or  fill out the patient inquiry form to learn more about potential participation in the Toca 5 study.

  • Learn More About The Toca 5 Trial

  • (Last Name Optional)
  • Toca 5 is open for patients with recurrent glioblastoma or anaplastic astrocytoma.
    View a list of participating sites.
  • ABOUT YOUR DATA

    We collect information you submit via inquiry forms and store it within our database. This information may be accessed by us in the future to respond to you, or to provide you with information that we believe helps to fulfill your request, or that would be of interest based on the nature and/or methodology of your inquiry. We don’t sell or distribute for marketing purposes your private information.

Toca 511 & Toca FC are investigational products. An investigational product is one that has not been proven to be safe and effective and is not licensed by the US Food and Drug Administration or any other government agency. An investigational product can only be administered in a research study.